Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8 Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Immunoglobulin G
  • Immunotoxins
  • Iodine Radioisotopes
  • Meningeal Neoplasms
  • Radioimmunotherapy

abstract

  • Intra-Ommaya 131I-3F8 was generally well tolerated; the maximum-tolerated dose was 10 mCi. A high CSF-to-blood ratio was achieved. Tracer studies reliably predicted the therapeutic dose to the CSF. Radioimmunoconjugates targeting GD2 may have clinical utility in the treatment of CNS/LM malignancies.

publication date

  • December 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.11.1807

PubMed ID

  • 18048828

Additional Document Info

start page

  • 5465

end page

  • 70

volume

  • 25

number

  • 34